Investigation of the Effects of Methylphenidate, an Amphetamine Derivative, on Intervertebral Disc Tissue Cell Cultures and Matrix Structures

Yasin Emre KAYA¹, Numan KARAARSLAN², Duygu YASAR SIRIN³, Hanefi OZBEK⁴, Necati KAPLAN⁵, Ibrahim YILMAZ⁴

¹Bolu Abant Izzet Baysal University, School of Medicine, Department of Orthopaedics and Traumatology, Bolu, Turkey
²Namik Kemal University, School of Medicine, Department of Neurosurgery, Tekirdag, Turkey
³Namik Kemal University, Faculty of Arts and Sciences, Department of Molecular Biology and Genetics, Tekirdag, Turkey
⁴Istanbul Medipol University, School of Medicine, Department of Medical Pharmacology, Istanbul, Turkey
⁵Istanbul Rumeli University, Corlu Reyap Hospital, Department of Neurosurgery, Tekirdag, Turkey

Corresponding author: Numan KARAARSLAN numikara@yahoo.com

ABSTRACT

AIM: To investigate the effects of methylphenidate (MPH), on intervertebral disc tissue (IVD) cell cultures and extracellular matrix structures. Changes in the expression of some important marker genes involved in anabolic and catabolic mechanisms of IVD extracellular matrix formation were also evaluated.

MATERIAL and METHODS: Primary cultures of nucleus pulposus cells (NPCs) and annulus fibrosus cells (AFCs) were isolated from tissues obtained from the operated patients. Cell viability and proliferation were tested, and the cell surface morphologies were evaluated by microscopy. The expressions of the chondroadherin (CHAD), cartilage oligomeric matrix protein (COMP), interleukin-1 beta (IL-1β) and matrix metalloproteinase (MMP) -7 and MMP-19 genes were evaluated using the quantitative real-time polymerase chain reaction (qRT-PCR). A value of p<0.05 was considered statistically significant.

RESULTS: The viability and proliferation of intervertebral disc tissue cells decreased in response to MPH treatment and the expression of the investigated genes also changed.

CONCLUSION: The data obtained from in-vitro studies may not directly adaptable to clinical applications. However, the fact that the central nervous system stimulant MPH can suppress proliferation of cells derived from IVD tissue should be considered carefully by clinicians.

KEYWORDS: Cartilage oligomeric matrix protein, Chondroadherin, Interleukin-1 beta, Intervertebral disc, Matrix metalloproteinase, Methylphenidate

INTRODUCTION

Methylphenidate (MPH) is a pharmacological agent used for the treatment of attention-deficit hyperactivity disorder (ADHD) due to its psychostimulant effect in children and adolescents aged between 6 and 18 years (6). MPH is often prescribed for patients with ADHD to improve attention and concentration and to reduce impulsive behaviors by increasing activities in certain areas of the brain that function below the normal level (7).

Some important cardiovascular and neurological side effects after the use of MPH have previously been reported (14,25,26). The relevant literature also indicates other side
effects, including swelling of the face, lips, tongue, or other parts of the body; shortness of breath or difficulty in breathing; rhabdomyolysis; and visual impairment (5,19). A variety of studies have also suggested that administration of MPH, an amphetamine derivative, may lead to a decrease in red blood cells, white blood cells, and platelets (6).

Some studies have reported that growth in almost every period of childhood may be adversely affected due to the induction of bone development disorders involving chondrodystrophies or the use of certain drugs (5,6). Indeed, a suppression of height increases in children has been reported after high-dose and long-term MHP administration (5,6). In addition to these known adverse events, invivo research has examined the adverse effects of MPH on human primary chondrocyte cultures (6). However, no studies have yet focused on the possible damage MHP administration may inflict on intervertebral disc (IVD) tissue. The aim of the present study was to investigate the potential effects of MPH, as a commonly prescribed drug for the treatment of patients with ADHD, on cultures of primary human nucleus pulposus cells (NPCs) and annulus fibrosus cells (AFCs). Cell viability, proliferation, and toxicity analyses were performed and the morphologies of cellular and matrix-like structures were also analyzed by microscopy.

The expression of chondroadherin (CHAD) (10), an NPC-specific marker, was also examined. The level of the cartilage oligomeric matrix protein (COMP) (3,8), an extracellular matrix protein that is involved in intervertebral disc catabolic metabolism, was also determined. In addition to these markers, the levels of matrix metalloproteinase (MMP)-7 and MMP-19 (16,23,24) and interleukin (IL-1β) (10), the main proinflammatory cytokine of the intervertebral disc, were examined using the quantitative reverse transcriptase real-time polymerase chain reaction (qRT-PCR).

MATERIAL and METHODS

The present research was approved by the Local Ethics Committee of Istanbul Medipol University (no. 29.11.2017-10840098/604.01.01/E.44192), Faculty of Medicine. Analyses were performed by the same researchers and repeated at least three times to minimize the experimental errors. Cell cultures were prepared from the tissues extracted from patients with spinal trauma who underwent operations after neurological examinations. Written consent forms were obtained from all the patients undergoing surgery whose tissues were used in the preparation of the primary cell cultures. Researchers were blinded to the dosages and drugs, i.e., the components in the culture medium. Primary cell cultures were fed every two days with freshly prepared culture medium. Cells reaching 95% confluency were assayed in third passages.

Materials

The 3 - (4, 5 - dimethylthiazol - 2 - yl) - 2,5- diphenyltetrazolium bromide (MTT) assay was performed using a commercial kit (Vybrant MTT Cell Proliferation Assay, Cat. no. V-13154; Cell Biolabs, USA). Gene expression assays were performed using a PureLink RNA Mini kit (cat. No. 12183018A; Ambion; Thermo Fisher Scientific, Inc.) and 2-mercaptopoethanol (Thermo Fisher Scientific, Inc.). Purified RNA (50 ng) was reverse transcribed to obtain complementary DNA (cDNA) using a High Capacity cDNA Reverse Transcription kit (cat. no. 4368814; Thermo Fisher Scientific, Inc.), according to the manufacturer’s protocol. The cDNA was used for the qPCR analyses to analyze the changes in gene expression using TaqMan Gene Expression Assays kits for CHAD (cat. no. 4331182, Hs00154382_m1); COMP (cat. no. 4331182, Hs00164359_m1), IL-1β (cat. no. 4331182, Hs01555410_m1), MMP -7 (cat. no. 4331182, Hs01042796_m1), and MMP-19 (cat. no. 4331182, Hs00418247_g1). β-actin (cat. no. 4331182, Hs01060665_g1; Thermo Fisher Scientific, Inc.) was used as the internal control (house keeping) gene. The Applied Biosystems 7300/7500 RT-PCR system was used for qRT-PCR.

Criteria for the Inclusion or Exclusion of the Tissues Obtained from the Patients

Of the 13 patients, the tissues of the following patients were excluded from the study: a patient with thyroid dysfunction (n=1), a patient with glaucoma (n=1), a patient with cerebral aneurysm (n=1), and a patient with paralysis (n=1). Two patients with a history of alcohol dependence (n=2) and a patient (n=1) using a monoamine oxidase inhibitor were also excluded. The remaining six patients (similar in terms of sex [3 male and 3 female], age, and body mass index) underwent operations and the resected IVD tissues from these patients were used for the preparation of primary cell cultures. Degenerated disc hernias compressing the nerve roots and/or the spinal cord were harvested, and the amount of disc degeneration was graded according to the Pfirrmann classification, using T2 weighted magnetic resonance imaging (MRI) scans (13). The ages of patients whose tissues (extruded or migrated disc fragments) were used varied from 22 years to 46 years, with a mean patient age of 36 ± 3.78 years.

Further examinations were performed for patients with lumbar disc herniation who were unresponsive to conservative medical treatment. The decision for surgical intervention was made following preoperative neurological examination and lumbar spinal MRI scans and, if necessary, following lumbar spinal computerized tomography (CT) and lower extremity electromyography (EMG). The patients were operated on in the prone position under general anesthesia. The surgical level was confirmed using C-arm scopy. Surgical site antisepsis was provided, and the site was kept covered in a sterile manner. A midline incision was made approximately 2 cm above the surgical level. After the skin was penetrated with an incision, the paravertebral muscles were dissected subperiosteally. A partial hemilaminectomy and flavectomy were subsequently performed. The dura and spinal root were identified and medialized following the flavectomy. The microdiscectomy was completed using a disc punch after the disc capsule was incised with a surgical steel scalpel (no. 15 blade) (9,13).

Following resection of the IVD tissue, the tissue samples were placed in sterile Falcon tubes containing Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 5% penicillin-streptomycin, 15% fetal bovine serum (FBS), and 1% L-glutamine. The samples were then transferred to

Kaya YE. et al: Cytotoxicity of Methylphenidate

Turk Neurosurg 29(5):734-742, 2019 | 735
the laboratory at 4°C. Falcon tubes were numbered so that researchers did not know which tissue sample had been obtained from which patient.

**Preparation of Cell Cultures from Human Primary IVD**

Tissue samples were irrigated consecutively three times with 0.9% isotonic sodium chloride solution in the laminar flow cabinet. The resulting mechanically degraded tissues were then transferred to Falcon tubes. A 0.375 mg sample of collagenase type II enzyme, dissolved in a complete medium, was added, and the samples were incubated overnight in 5% CO₂ at 37°C. The samples were then centrifuged twice at 1200 rpm [112 Relative Centrifugal Force (RCF)] for 5 minutes, following the protocol described by Karaarslan et al. (9-13,21). The obtained cell pellets were resuspended in cell culture medium and transferred to flasks. Confluent primary cell cultures were passaged. At the third passage, the cells were stained with trypan blue and counted under an inverted light microscope at 10x magnification. The counted cells were then transferred to various well plates to perform analyses. All the cell samples were then incubated in an incubator at 37.4°C with 5% CO₂.

**MPH Treatment of Cell Cultures**

The primary stock solution of MPH was made by dissolving 10 mg in 4300 μM dimethyl sulfoxide as described previously (1) and then diluted to 10, 100, 250, and 1000 μM final concentration and added to the primary cell cultures isolated from IVD tissue. All the analyses were performed at 0, 24, 48, and 72 hours (h).

**Inverted Light/Fluorescence Microscopy and Acridine Orange & Propidiumiodide Staining**

Cell surface morphologies were examined under 4x, 10x, 20x, and 40x magnifications using an inverted light microscope (Olympus CKX41) and a fluorescence microscope (Leica; DM 2500). Analyses were performed at 24, 48, and 72 h.

Cell viability was determined and the results of the MTT assay were confirmed using the nucleic acid binding dyes acridine orange (AO) and propidium iodide (PI). To prepare the AO/PI stain, 4 mg AO (dissolved in 2 ml 99% ETOH), 10 g sodiumethylenediaminetetraacetic acid, 4mg PI, and 50ml FBS were mixed well and sterile distilled water was added to reach a 200ml final volume (9,11-13,21). The AO generates green fluorescence and stains all nucleated cells, whether alive or dead. By contrast, PI stains nucleated cells, but only dead cells with poor membrane integrity and generates red fluorescence. Microphotographs of cell organization were visualized using Cytovision Capture Station Imaging software.

**MTT Assay**

Cell viability analyses were performed using a commercial MTT kit. The MTT analyses were performed in all the control and experimental group samples before and after the drug administration. Analyses were performed at a wave length of 570 nm with an enzyme-linked immunosorbent assay (ELISA/Optical density-OD) microplate reader (Mindray MR 96 A, PRC). The culture media containing MPH discarded from the 100 mL MTT wells (12 mM/5 mg MTT prepared by adding 1 mL sterile phosphate buffer saline) was added. Cultures were incubated at 37 °C for 3 h in the dark. Dimethyl sulfoxide was added to these samples to stop the reaction and incubated at 37 °C for an additional 10 minutes, followed by spectrophotometric absorbance measurements at 570 nm. The control group consisted of cells without MPH administration and the control cell viability was taken as 100%. The proliferation and the inhibition of the proliferation were calculated using the following formulas: “Test OD/ Control OD100” and “1- Test OD/ Control OD.” respectively, and the data were recorded for statistical analysis (6,9-11,13,21).

**Gene Expression Analysis by qRT-PCR**

Total RNA was extracted from cultured primary human chondrocytes using the PureLink RNA mini kit. The quantity of RNA obtained from each sample was measured using a spectrophotometer. The cDNA was obtained by reverse transcription of 50 ng RNA using a high capacity cDNA reverse transcription kit and a thermal cycler. All genes were amplified using TaqMan® Gene Expression assays for CHAD, ACTβ, COMP, MMP-7, MMP-19, and IL-1β. The qPCR was performed on an Applied Biosystems 7300/7500 real-time PCR system (Thermo Fisher Scientific, Inc.), and the reaction mixture consisted of 1 μlTaqMan gene expression assay, 10 μlTaqMan gene expression master mix, 4 μl cDNA template, and UltraPure DNase/RNase free distilled water for each gene, conducted in MicroAmp fast optical 96 well reaction plates. The thermocycling conditions were as follows: 2 min at 50°C, 10 min at 95°C, 15 sec at 95°C, and 1 min at 60°C, for 40 cycles. The RQ values of each sample from the RTqPCR experiment were obtained using the 7500 FastSDS program V.2.3 (Thermo Fisher Scientific, Inc.). An endogenous control (ACTβ) was utilized to normalize the target gene expression (9-13,21).

**Statistical Analysis**

The statistical analyses were performed using Minitab (version 16.0, Minitab Ltd., Coventry, United Kingdom) software. Descriptive statistics were presented as the mean ± standard deviation (M ± SD). An analysis of variance (ANOVA) test was performed to test for significant differences across the group means. When differences across groups were observed, Tukey’s honestly significant difference (HSD) post-hoc test was used for multiple pairwise comparisons. The alpha significance value was accepted as <0.05.

**RESULTS**

The control group samples were viable and healthy and had a proliferation rate that reached approximately 95% confluency. In the control group cultures at 72 h, the cells formed apophyses that spread to the extracellular matrix or a larger area (Figure 1A-C). However, the cell viability of the MPH-treated samples showed time- and dose-dependent decreases. The characteristic morphology of the cells was disrupted, and the cells became rounder (Figure 1D-O).
Figure 1: Evaluation of nucleus pulposus and annulus fibrosus cells by inverted light microscopy. The inverted light microscopy images were taken at magnifications of 10x, 20x, and 40x.
The AO/PI staining revealed that MPH caused apoptotic cell death (Figure 2A-O). Although the application of highest dose MPH was expected to result in the greatest increase in cell death, the highest cell death was observed at 24 h following the administration of 100 µM MPH. The cell viability and proliferation gradually decreased in a time-dependent manner with increasing MPH concentration, and the differences were statistically significant (F=14; p=0.000) (Table I).

All the gene expressions, except for MMP-19, increased with time in the control group samples. The expression of MMP-19 remained unchanged at 72 h. Administration of 10 µM MPH decreased the expression of CHAD approximately 2-fold (RQ=0.32) at 24 h, 1.6-fold at 48 h, and 3.5-fold at 72 h when compared to the control group. Administration of 100 µM MPH eliminated CHAD expression at 24 h and decreased the expression 1.6-fold at 48 h and 5.2-fold at 72 h when compared to the control group samples. Administration of 250 µM MPH decreased CHAD expression approximately 1.6-fold (RQ = 0.41) at 24 h, 2.4-fold at 48 h, and 2.2-fold at 72 h when compared to the control group samples. Administration of 1000 µM MPH eliminated CHAD expression at 24 h; however, CHAD expression was the same as in the control group at 48 h, and it remained unchanged at 72 h, so CHAD expression was less affected by administration of 1000 µM MPH.

Administration of 10 µM MPH decreased COMP expression approximately 4.4-fold at 24 h, 1.4-fold at 48 h, and 1.7-fold at 72 h, when compared to the control group. Administration of 100 µM MPH decreased COMP expression 2.4-fold at 24 h, 1.7-fold at 48 h, and 1.5-fold at 72 h, when compared to the control group. Administration of 250 µM MPH increased COMP expression 0.8-fold at 24 h and decreased COMP expression 2.6-fold at 72 h, when compared to the control group. However, COMP was expressed at the same level as in the control group at 48 h. Administration of 1000 µM MPH resulted in no change in COMP expression at 24 h; however, COMP expression was increased 0.6-fold at 48 h and 0.4-fold at 72 h, when compared to the control group.

Administration of 10 µM MPH decreased IL-1β expression 2.1-fold at 24 h, 2.4-fold at 48 h, and 3.1-fold at 72 h. Administration of 100 µM MPH increased IL-1β expression 0.8-fold at 24 h, but decreased IL-1β expression 3.8-fold at 48 h, and 2.8-fold at 72 h. Administration of 250 µM MPH decreased IL-1β expression 2.8-fold at 24 h, but expression remained at the control level at 48 h and 72 h. Administration of 1000 µM MPH decreased IL-1β expression 3.2-fold at 24 h, 3.6-fold at 48 h, and 4.3-fold at 72 h, when compared to the control group.

Table I: Evaluation of the Effects of MPH, Administered Different Concentrations, on the Cell Viability Through Tukey HSD Test After ANOVA

<table>
<thead>
<tr>
<th>Groups vs Times</th>
<th>Hours (h)</th>
<th>n</th>
<th>Mean ± SD*</th>
<th>Grouping¥</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>72</td>
<td>8</td>
<td>0.374 ± 0.01</td>
<td>A</td>
</tr>
<tr>
<td>Control</td>
<td>48</td>
<td>8</td>
<td>0.325 ± 0.02</td>
<td>A B</td>
</tr>
<tr>
<td>Control</td>
<td>24</td>
<td>8</td>
<td>0.311 ± 0.01</td>
<td>A B C</td>
</tr>
<tr>
<td>Control</td>
<td>0</td>
<td>8</td>
<td>0.289 ± 0.01</td>
<td>C D</td>
</tr>
<tr>
<td>MPH 1 µM</td>
<td>24</td>
<td>8</td>
<td>0.284 ± 0.01</td>
<td>B C D E</td>
</tr>
<tr>
<td>MPH 1 µM</td>
<td>48</td>
<td>8</td>
<td>0.274 ± 0.01</td>
<td>C D E</td>
</tr>
<tr>
<td>MPH 100 µM</td>
<td>24</td>
<td>8</td>
<td>0.272 ± 0.01</td>
<td>C D E F</td>
</tr>
<tr>
<td>MPH 1 µM</td>
<td>72</td>
<td>8</td>
<td>0.269 ± 0.01</td>
<td>C D E F G</td>
</tr>
<tr>
<td>MPH 100 µM</td>
<td>48</td>
<td>8</td>
<td>0.264 ± 0.02</td>
<td>D E F G</td>
</tr>
<tr>
<td>MPH 500 µM</td>
<td>24</td>
<td>8</td>
<td>0.262 ± 0.01</td>
<td>D E F G H</td>
</tr>
<tr>
<td>MPH 500 µM</td>
<td>48</td>
<td>8</td>
<td>0.262 ± 0.02</td>
<td>D E F G H</td>
</tr>
<tr>
<td>MPH 1000 µM</td>
<td>24</td>
<td>8</td>
<td>0.253 ± 0.02</td>
<td>D E F G H</td>
</tr>
<tr>
<td>MPH 1000 µM</td>
<td>48</td>
<td>8</td>
<td>0.249 ± 0.02</td>
<td>E F G H</td>
</tr>
<tr>
<td>MPH 100 µM</td>
<td>72</td>
<td>8</td>
<td>0.242 ± 0.01</td>
<td>F G H</td>
</tr>
<tr>
<td>MPH 500 µM</td>
<td>72</td>
<td>8</td>
<td>0.232 ± 0.02</td>
<td>G H</td>
</tr>
<tr>
<td>MPH 1000 µM</td>
<td>72</td>
<td>8</td>
<td>0.221 ± 0.01</td>
<td>H</td>
</tr>
</tbody>
</table>

Figure 2: Evaluation of intervertebral disc tissue cells by fluorescence microscopy. The cells in groups with high concentrations of methylphenidate (MPH) and showing red nuclei and green cytoplasm are dead and have damaged membrane integrity.
Administration of 10 µM and 250 µM MPH resulted in no change in MMP-19 expression when compared to the control group. Administration of 1000 µM MPH increased MMP-19 expression 0.7-fold at 72 h, when compared to the control group. At all other doses, administration of MPH decreased MMP-19 by 1.4-fold to 1.9-fold at 24, 48, and 72 h, when compared to the control group.

Administration of 10 µM MPH eliminated MMP-7 expression at 24 h, and no MMP-7 expression was detected at 72 h following administration of 250 µM MPH. MMP-7 expression was decreased 2.5-fold at 24 by administration of 250 µM MPH, while it was increased 0.3-fold and 0.7-fold, respectively, following administration of 100 and 1000 µM MPH. MMP-7 expression was increased 08.-fold at 48 h after administration of 1 µM MPH, where as it was decreased 4.0-fold, 3.8-fold, and 1.3-fold, respectively, by administration of 100, 250, and 1000 µM MPH. MMP-7 expression was more strongly decreased at 72 h, where it showed decreases of 7.6-fold, 7.3-fold, and 2.8-fold, respectively, following administration of 1, 100, and 1000 µM MPH (p<0.05). The RQ values obtained through qRT-PCR analyses are presented in Figure 3.

**DISCUSSION**

Many drugs are known to accumulate in many tissues in the body, including the synovial fluid compartments (9-13,21). Hence, drugs can diffuse from hyaluronan and synovial tissues into body fluids (9-13,21) and they can pass through pores in the hyaline membranes located in the intervertebral disc space to reach the IVD cells (9,21). In humans, the IVD tissue is fed through the arterial blood until the age of 18. In the late twenties and early thirties, vascular feeding of the whole nucleus pulposus tissue and the peripheral part of the annulus fibrosus tissue is obliterated, and the disc tissue is then fed by diffusion from the environment that surrounds it (9-11,13,21).

Gumustas et al. demonstrated the accumulation of MPH in synovial tissues (6), and reported a decrease in the viability, proliferation, and stage-specific embryonic antigen-1 protein expression in MHP-treated chondrocytes when compared to the control group. These researchers therefore cautioned clinicians not to overlook the fact that this drug may suppress chondrocyte cell proliferation and chondrogenic differentiation (6). However, in that study, the effects of MHP on cartilage tissues were solely investigated in vitro (6).

Overall, the results retrieved from the studies related to the treatment of ADHD using MPH are quite confusing. In *in vivo* studies, MPH administration to young rats has been reported to result in smaller, less mineralized, and weaker bones in the appendicular region, and deteriorated bone quality (15). These findings agree with reports that adolescents treated with MPH have a high potential for long bone fractures. For example, the study by Batterson et al. (1), performed before 2005, concluded that MPH administration in children and adolescents might suppress growth and that delayed growth was associated with delayed tooth growth. However, Tehranchi et al. evaluated the dental age and cervical vertebral maturation in a study that also investigated ADHD for its potential role in delayed growth and development of children and reported that the deterioration of cervical vertebral maturation observed in children treated with MPH was also present in children not treated with MPH (22). No previous studies have focused on the positive or negative effects of MPH on disc tissue cells, such as IVD tissues or AFCs/NPCs. The aim of the present study was to investigate the potential effects of MPH, commonly prescribed for the treatment of patients with ADHD, on cells from human articular primary disc tissues.

Ludolph et al. reported that although MPH was the most commonly used drug in child and adolescent psychiatry, the knowledge of the pharmacological mechanism of MHP was incomplete (17). The authors investigated the toxic effects of MPH *in vitro* in HEK-293 and HEK-hDAT cells and found that doses up to 1 mM did not affect the growth of HEK-hDAT cells or the survival of dopaminergic (DA) neurons for up to 72 hours. In that study, no differences in neuronal arborization or in the density of synapses were observed. Administration of 1-methyl-4-phenylpyridinium showed no toxic effect in HEK-293 cells but had marked toxic effects in HEK-hDAT cells and DA neurons (17).

Bigler et al. reported that psychoactive drugs, such as MPH, caused different stress hormone profiles (2). Luethi et al. investigated MPH-based designer drugs and tested the potencies...
of the MPH-based N-benzylethylphenidate, 3,4-dichloroethylphenidate, 3,4-dichloromethylphenidate, ethylphenidate, ethylphenidate, 4-fluoromethylphenidate, isopropylphenidate, 4-methylmethylphenidate, methylmorphenate, and propylphenidate, as well as the potencies of the relevant compounds cocaine and modafinil, in terms of norepinephrine, dopamine, and serotonin transporter inhibition in HEK-293 cells (18). In that study, monoaamine efflux, monoaamine receptor, and transporter binding affinities were also investigated. The authors concluded that the MPH-based substances inhibited the norepinephrine and dopamine transporters with 4 to 1000-fold greater potency when compared with the serotonin transporter (18). The MPH-based substances did not induce transporter-mediated flow of monoamines, as this flow was the same for MPH as for cocaine (18). The authors emphasized that many test drugs had an affinity for adrenergic, serotonergic, and rat trace amine-associated receptors, but not for DA or mouse trace amine-associated receptors (18). No cytotoxicity was observed after drug treatment at the analyzed concentrations, and MPH-based chemicals were reported to have pharmacological effect profiles similar to those of MPH and cocaine (18).

The results obtained from studies based on animal models may differ from those obtained in human studies, so that the results may be misleading (6,10). The sensitivities of human and animal tissues differ, and commercial cell lines contain a single type cell and do not have their original phenotypic and genotypic characteristics (6,9-11). For these reasons, in the present study, we did not use animal tissues or commercial cell lines. Instead, we prepared human primary cell cultures from intact human intervertebral disc tissue. We believe that this difference may contribute to the value of the present study.

These human primary cell cultures were used to examine the effects of MPH on the expression of several important genes in IVD tissues. CHAD is a cartilage matrix protein that promotes the adhesion of NPCs, chondrocytes, fibroblasts, and osteoblasts (12,13), mediated by integrin alpha and beta (11). CHAD therefore plays a significant role in the regulation of chondrocyte growth and proliferation (11-13). The COMP gene encodes the cartilage oligomeric matrix protein found in the extracellular matrix of the cells that make up ligaments and tendons and the near cartilage-forming cells. COMP plays a role in cell growth and proliferation, as well as in the regulation of cell movement and attachment. It may also be involved in the pathogenesis of osteoarthritis and may serve as a potent suppressor of apoptosis in primary chondrocytes, intervertebral disc cells, and transformed cells (11-13). IL-1β is a proinflammatory cytokine that induces prostaglandin synthesis; neutrophil influx and activation; T-cell activation and cytokine production; B-cell activation and antibody production; and fibroblast proliferation and collagen production in the extracellular matrix (20,28). MMP-7 and MMP-19 are members of the matrix metalloproteinase (MMP) family consisting of structural-related zinc-dependent endopeptidases. The primary role of cleaved/activated MMP is to break down the extracellular matrix by degrading macromolecules like casein, gelatin, fibronectin, and proteoglycan (4,27). Cell viability and proliferation were gradually decreased as the exposure to MPH increased. The results of the qRT-PCR analysis indicated that differences in the applied doses and the durations of administration changed the expressions of all the genes. The analyses were repeated three times using samples obtained from six patients; however, the small sample size precluded the demonstration of a clear correlation between dosage and gene expression changes. The MTT analysis and AO/PI staining revealed a decrease in cell proliferation and apoptotic cell death. Although the administration of the highest dose MPH was expected to increase cell death, the highest cell death was observed following the application of 100 µM MPH at 24h, in agreement with the qRT-PCR analyses. The lowest gene expression change was actually observed following the highest dose administration.

In humans, MPH is metabolized in the liver in the form of phenyl piperidine acetic acid (PPAA), which has little or no pharmacological activity. The present study was carried out in an in vitro environment, so the effect of PPAA, a de-esterified metabolite, on IVD tissue cells cannot be clearly explained. The present study has a number of limitations, so studies that incorporate a larger number of participants should be performed to provide a clear explanation.

**CONCLUSION**

The data obtained from in vitro studies may not be directly adaptable to clinical applications. However, the fact that MPH—a central nervous system stimulant pharmaceutical preparation frequently prescribed for the treatment of ADHD, narcolepsy, and chronic fatigue syndrome—may suppress IVD tissue cell proliferation should be considered carefully by clinicians.

**REFERENCES**


